MARKET WIREYahoo! Finance Canada • 8h ago
argenx SE (ARGX) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
Why ARGX Stock slipped -0.56% Today — RQD Quant Desk Flash
$892.87 -0.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $890.27
argenx SE (ARGX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $55.72B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ARGX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ARGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, argenx SE (NASDAQ: ARGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $892.87 (-0.56% 1D, market cap $55.72B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ARGX ranks #142 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ARGX compare to RVMD and BIIB in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARGX carries a Roarable C (63/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, RVMD (Revolution Medicines Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -28.6%, cap $40.78B) and BIIB (Biogen Inc.) posts a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ARGX?
▼
For argenx SE (ARGX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #142 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $890.28 (-0.29%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 15.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARGX)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY ARGX SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (22% of score)
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 51.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$802.64+8.4% Next Q
55
Q2 (-2Q)Grade C$869.72+1.5% Next Q
58
Q3 (-1Q)Grade C$882.48+1.2% Next Q
60
CurrentGrade C$892.87+0.9% Hist 90D α
63
Trajectory: C (55) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the ARGX Bull Thesis Could Fail
Even with a 63/100 (C) score, ARGX faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($938.51) or 200D SMA ($855.64) invalidates the momentum regime and cuts Target Base ($912.96) toward Bear Floor ($712.11).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARGX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARGX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ARGX Stock slipped -0.56% Today — RQD Quant Desk Flash
argenx SE (ARGX) slipped -0.56% to $892.87, trading at 56% of its 52-week range ($661.85 – $1072.75). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 56% of its 52-week range ($661.85 – $1072.75) with RSI-14 at 51.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.1% around $892.87 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $1.2B annual free cash flow.
Live ARGX Headlines & Catalysts
RISK WATCHBarchart.com • 11h ago
ARGX Stock Sinks as Argenx Scraps Late-Stage TrialBarchart.com report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 14h ago
argenx SE (ARGX) stock price, news, quote and historyYahoo Finance Singapore report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeeking Alpha • 17h ago
Argenx stock falls on late-stage trial setback (ARGX:NASDAQ)Seeking Alpha report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Motley Fool • 20h ago
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?The Motley Fool report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 23h ago
argenx SE Stock (ARGX) Moved Down by 13.36% on Oct 8: A Full AnalysisTradingKey report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 1d ago
Argenx Se Stock Price Forecast. Should You Buy ARGX?StockInvest.us report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Why Is Argenx Stock Tumbling Today? - argenx (NASDAQ:ARGX)Benzinga report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
MARKET WIREYahoo • 4d ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingEuropean equities traded in the US as American depositary receipts were tracking higher late Thursda
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (ARGX Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ARGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.08%📐 HORIZONTAL RANGE
2026-11-02O $891.8H $897.9L $891.8C $892.9VOL 161.0K
RES: $1,192.1SUP: $775.6SMA50: $938.5SMA200: $855.6
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ARGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth
vs. +18.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ARGX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ARGX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARGX)
Health Care Rank #142 of 1016
⚔️ RVMD vs ARGX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ARGX vs. RVMD, BIIB, MRNA, BNTX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, argenx SE (ARGX) ranks #142 by composite RQD confidence (63/100, grade C) and #35 by equity capitalization ($55.72B). Within this direct 5-issuer industry benchmark cohort, BIIB leads on earnings valuation at 28.5x trailing P/E, while ARGX leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BIIB currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ARGX at 63/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARGX
ACTIVE
argenx SE | C | 63/100 | 32.8x | — | 9.9% | -0.56% | $55.72B | Benchmark Subject |
| RVMD Revolution Medicines Inc. | D+ | 55/100 | — | — | -28.6% | +0.55% | $40.78B | /rvmd-vs-argx → |
| BIIB Biogen Inc. | B | 74/100 | 28.5x | 75.7% | 6.4% | +1.59% | $36.90B | /biib-vs-argx → |
| MRNA Moderna Inc. | C- | 60/100 | — | 55.3% | -34.1% | -0.47% | $88.93B | /mrna-vs-argx → |
| BNTX BioNTech SE | D+ | 52/100 | 32.8x | — | 9.9% | -1.08% | $22.39B | /bntx-vs-argx → |
2. ARGX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTargenx SE (ARGX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $55.72B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. ARGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ARGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, argenx SE (NASDAQ: ARGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $892.87 (-0.56% 1D, market cap $55.72B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ARGX ranks #142 in composite RQD confidence.
How does ARGX compare to RVMD and BIIB in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARGX carries a Roarable C (63/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, RVMD (Revolution Medicines Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -28.6%, cap $40.78B) and BIIB (Biogen Inc.) posts a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ARGX?
For argenx SE (ARGX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #142 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ARGX trading relative to its 50-day, 200-day, and 52-week technical levels?
ARGX last traded at $892.87 (-0.56% on volume of 462,634 shares), positioning the stock -4.86% below its 50-day simple moving average ($938.51) and +4.35% above its 200-day simple moving average ($855.64). Across its 52-week range of $661.85 to $1,072.75, ARGX sits at the 56.2% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($838.40 to $947.34).
ARGX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ARGX stock moving today?
Why ARGX Stock slipped -0.56% Today — RQD Quant Desk Flash. Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 63/100 (C)
✓ STAGE-C NUMBER FIREWALL VERIFIED
ARGX — argenx SE: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:08:38Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating is 63 / C, labeled "Roarable Hold — Fair / Balanced Risk-Reward," per the Roarable RQD rating. Across its five pillars:
- Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this reflects ROIC of 9.9% and an FCF yield of 2.21%. Those figures indicate a moderate return on invested capital but a thin free-cash-flow yield relative to the $55.72B market cap, which places valuation weight on future cash generation.
- Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, so institutional flow is a weaker support for the thesis than the other pillars.
- Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The score is modestly below midpoint.
- Macro Regime Fit: 14 / 20. Per the Roarable RQD rating, beta is 1.02 and the pillar reflects sector sensitivity. A beta near 1.0 means the stock has tended to move broadly with the market rather than amplifying it.
- Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. This is the strongest pillar and the main offset to weaker cash-flow and flow metrics.
For a prospective investor, the rating describes a balanced setup. The balance sheet is the firmest support. Valuation is the main tradeoff: per the market data, P/E (TTM) is 32.8 and forward P/E is 27.6, with EV/EBITDA of 21, which prices in meaningful earnings growth. Upside drivers would be earnings delivery and sustained institutional accumulation; the weakest pillars (whale flow, insider conviction) are where the thesis is least confirmed. This is an analytical framing, not personalized advice.
Snapshot
Open Questions
- What specific late-stage trial was scrapped, and what is its revenue or pipeline significance for argenx?
- What are the reported revenue, operating income, net income, FCF, cash, and debt figures across periods, given that the financials section is empty?
- What is the analyst consensus rating and price target distribution behind the reference to targets of at least $1,200?
- Why is gross margin recorded as 0%, and what does that reflect in the reporting?
- Which institutions and insiders are accumulating or selling, given the empty holders section?
ARGX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for argenx SE (ARGX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 8h ago
argenx SE (ARGX) Stock Price, News, Quote & History Yahoo! Finance Canada report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Barchart.com • 11h ago
ARGX Stock Sinks as Argenx Scraps Late-Stage Trial Barchart.com report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 14h ago
argenx SE (ARGX) stock price, news, quote and history Yahoo Finance Singapore report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 17h ago
Argenx stock falls on late-stage trial setback (ARGX:NASDAQ) Seeking Alpha report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 20h ago
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? The Motley Fool report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 23h ago
argenx SE Stock (ARGX) Moved Down by 13.36% on Oct 8: A Full Analysis TradingKey report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Argenx Se Stock Price Forecast. Should You Buy ARGX? StockInvest.us report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Why Is Argenx Stock Tumbling Today? - argenx (NASDAQ:ARGX) Benzinga report covering argenx SE (ARGX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ARGX Bull vs. Bear Conversation Board — What's Your Call at $892.87?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARGX 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $969.68 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is ARGX (C • RQD 63/100) a Buy at $897.85?
Welcome to the ARGX (argenx SE) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $754.19 (-16.0%)
Spot @ $897.85 Pump the brakes on ARGX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on ARGX, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless argenx SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1,113.33 (+24.0%)
Spot @ $897.85 ARGX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on ARGX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $897.85 (52-wk range $661.85 - $1072.75), any beat on forward guidance forces shorts and underweight funds to chase.